Suppression of Nicotinamide Phosphoribosyltransferase Expression by Mir-154 Reduces the Viability of Breast Cancer Cells and Increases Their Susceptibility to Doxorubicin Publisher Pubmed



Bolandghamat Pour Z¹ ; Nourbakhsh M² ; Mousavizadeh K^{1, 3} ; Madjd Z^{1, 4} ; Ghorbanhosseini SS⁵ ; Abdolvahabi Z⁶ ; Hesari Z^{7, 8} ; Ezzati Mobasser S² Show Affiliations
Source: BMC Cancer Published:2019

Abstract

Background: Nicotinamide phosphoribosyltransferase (NAMPT) enzyme acts as the major enzyme in the nicotinamide adenine dinucleotide (NAD) synthesis salvage pathway. Deregulation of NAD could be associated with progression of several cancers such as breast cancer. Here, the consequence of NAMPT inhibition by miR-154 was investigated on breast cancer cells. Methods: MDA-MB-231 and MCF-7 cancer cell lines were transfected with the mimic and inhibitors of miR-154-5p and their corresponding negative controls. Consequently, levels of NAMPT and NAD were assayed employing qRT-PCR, Western blotting and enzymatic method, respectively. Subsequently, flow cytometry and colorimetric methods were performed to evaluate apoptosis and cell viability. Bioinformatics analyses as well as luciferase assay were done to investigate whether the 3′-UTR of NAMPT is directly targeted by miR-154. Results: According to the obtained results, NAMPT was recognized as a target for binding of miR-154 and the levels of this miRNA was inversely associated with both mRNA and protein levels of NAMPT in breast cancer cell lines. Functionally, miR-154 inhibited the NAD salvage pathway leading to a remarkable decrease in cell viability and increased rate of cell death. When breast cancer cells were simultaneously treated with doxorubicin and miR-154 mimic, cell viability was considerably reduced compared to treatment with doxorubicin alone in both cell lines. Conclusions: It was concluded that the inhibition of NAD production by miR-154 might be introduced as an appropriate therapeutic approach in order to improve breast cancer outcome either alone or in combination with other conventional chemotherapeutic agents. © 2019 The Author(s).